Výsledky vyhledávání - "Vincent J. Wacher"

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

Autor: Vincent J. Wacher, Tracey M. Roberts, Olivia Coughlin, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Ralph Stevenson, Chenxiong (Charles) Le

Publikováno v: The Lancet. Infectious diseases. 19(5)

Infections with Clostridium difficile are a health threat, yet no products are currently licensed for prevention of primary C difficile infections. Intravenous β-lactam antibiotics are considered to confer a high risk of C difficile infection becaus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6337d9ea89986147a7e037836d826697
https://pubmed.ncbi.nlm.nih.gov/30885590

Zobrazit plný text záznamu

SYN-004 (Ribaxamase), an Orally Administered β-Lactamase for Prevention of Clostridium Difficile Infection in Patients Treated with Intravenous β-Lactam Antibiotics: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study

Autor: John F. Kokai-Kun, Tracey M. Roberts, Ralph Stevenson, Joseph Sliman, Vincent J. Wacher, Heidi Whalen, Olivia Coughlin, Chenxiong (Charles) Le

Publikováno v: SSRN Electronic Journal.

Background: Clostridium difficile infection (CDI) is an urgent public health threat, yet there is no product currently licensed for its prevention. The use of intravenous β-lactam antibiotics are considered high risk for the development of CDI due t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59055f69e51c731ca0c65a13a3d42c48
https://doi.org/10.2139/ssrn.3234882

Zobrazit plný text záznamu

Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study

Autor: Richard J. Simpson, Robert MacGinley, Geoffrey C. Nicholson, Kerrie M. Sanders, Kathy Skoff, Ken Walder, Neil Orford, Guy Y. Krippner, Alana Sarah, Joseph Proietto, Gabrielle Phillips, Vincent J Wacher, Jo Chambers

Publikováno v: Diabetes Care. 37:3121-3123

OBJECTIVE To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e1abda875ba7b25d9f7acab53a3b514
https://doi.org/10.2337/dc14-1038

Zobrazit plný text záznamu

Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS

Autor: Kevin J. Edgar, Michael F. Wempe, Karen M. Ruble, Vincent J. Wacher, Janet Lightner, James L. Little, Charles Michael Buchanan, Charles Wright, George B. Caflisch, Shannon E. Large, Peter J. Rice

Publikováno v: International Journal of Pharmaceutics. 370:93-102

Tocopheryl Polyethylene Glycol Succinate 1000 (TPGS 1000) can inhibit P-glycoprotein (P-gp); TPGS 1000 was not originally designed to inhibit an efflux pump. Recent work from our laboratories demonstrated that TPGS activity has a rational PEG chain l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2911f50f4cae0bf6eca7541d104b923
https://doi.org/10.1016/j.ijpharm.2008.11.021

Zobrazit plný text záznamu

Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole‐cyclodextrin formulations

Autor: Sandra Klein, Michael G. Ramsey, Charles Michael Buchanan, Kevin J. Edgar, Norma Lindsey Buchanan, Vincent J. Wacher, James L. Little, Michael F. Wempe, Karen M. Ruble

Publikováno v: Journal of Pharmaceutical Sciences. 96:3100-3116

The current research evaluated and compared the efficacy of hydroxybutenyl-beta-cyclodextrin (HBenBCD) and hydroxypropyl-beta-cyclodextrin (HPBCD) as enhancers of itraconazole solubility and oral bioavailability. At 10 wt% cyclodextrin, 17-fold and 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215e591953e1ebe8a9d53ded89ccc402
https://doi.org/10.1002/jps.20878

Zobrazit plný text záznamu

Pharmacokinetics of Tamoxifen after Intravenous and Oral Dosing of Tamoxifen–Hydroxybutenyl-β-Cyclodextrin Formulations

Autor: Michael Orlando Malcolm, Karen M. Ruble, Vincent J. Wacher, Michael F. Wempe, Kevin J. Edgar, Norma Lindsey Buchanan, James L. Little, Charles Michael Buchanan

Publikováno v: Journal of Pharmaceutical Sciences. 96:644-660

Oral and intravenous administration of tamoxifen base and tamoxifen citrate formulated with hydroxybutenyl-beta-cyclodextrin (HBenBCD) to Sprague-Dawley rats significantly increased the oral bioavailability of tamoxifen relative to that of parent dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b24367dfda73f2d6ceab5c45fedd1a8
https://doi.org/10.1002/jps.20709

Zobrazit plný text záznamu

Sirolimus Oral Absorption in Rats Is Increased by Ketoconazole but Is Not Affected by d-α-Tocopheryl Poly(Ethylene Glycol 1000) Succinate

Autor: Jeffrey A. Silverman, Vincent J. Wacher, Daniel J. O'Mahony, Amy O. Chan, Paulina Tran-Tau, Susan Wong, Zeibun Ramtoola, Anne Chai, Xiang-Qing Yu

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 303:308-313

The contributions of cytochrome P450 3A (CYP3A) and P-glycoprotein to sirolimus oral bioavailability in rats were evaluated by coadministration of sirolimus (Rapamune) with the CYP3A inhibitor ketoconazole or the P-glycoprotein inhibitor D-alpha-toco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abc233e1450f0a5cc29525076463ad78
https://doi.org/10.1124/jpet.102.036541

Zobrazit plný text záznamu

Minimal effect of ketoconazole on cyclosporine (SangCyATM) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption

Autor: Vincent J. Wacher, Harrison T. Wong, Susan Wong

Publikováno v: Biopharmaceutics & Drug Disposition. 23:53-57

The current work evaluated the effect of the CYP3A inhibitor ketoconazole on the oral absorption and first-pass metabolism of cyclosporine administered as the SangCyA formulation. Groups of 6 male Sprague–Dawley rats were administered SangCyA (5 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8eb1fea637a63211a2942b5b33d080
https://doi.org/10.1002/bdd.295

Zobrazit plný text záznamu

[Untitled]

Autor: Leslie Z. Benet, Miki Susanto, Andrea Soldner, Vincent J. Wacher, Jeffrey A. Silverman, Uwe Christians

Publikováno v: Pharmaceutical Research. 16:478-485

Purpose. Grapefruit juice (GJ) is known to increase the oral bioavailability of many CYP3A-substrates by inhibiting intestinal phase-I metabolism. However, the magnitude of AUC increase is often insignificant and highly variable. Since we earlier sug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e61627047850adc5da9f667d6ddc8530
https://doi.org/10.1023/a:1011902625609

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání